GlassScriptPhysician profile
Vera Maranci
NPI 1922207588
$917.72
in general payments reported to CMS, 2019-2025
22 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $181 · 2022: $118 · 2023: $144 · 2024: $358 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $618.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $110.42 | 2021-2025 | |
| Astellas Pharma US INC | $105.98 | 2021-2025 | Xtandi, Padcev |
| Gilead Sciences, INC. | $98.64 | 2022-2024 | Trodelvy |
| Pfizer INC. | $64.18 | 2021-2024 | |
| Sumitomo Pharma America, INC. | $60.19 | 2023-2024 | Orgovyx |
| Glaxosmithkline, LLC. | $56.57 | 2024 | Ojjaara |
| Emd Serono, INC. | $43.80 | 2022 | |
| Array Biopharma INC | $39.83 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Servier Pharmaceuticals LLC | $37.96 | 2024-2025 | |
| Seagen INC. | $37.21 | 2021-2023 | Adcetris |
| Amgen INC. | $36.37 | 2021-2023 | Lumakras |
| E.R. Squibb & Sons, L.L.C. | $35.95 | 2022-2024 | Krazati |
| Abbvie INC. | $30.12 | 2024 | |
| Genzyme Corporation | $24.28 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $22.00 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $20.81 | 2021 | |
| Celgene Corporation | $19.69 | 2023 | Reblozyl |
| Kite Pharma, INC. | $16.87 | 2024 | Yescarta |
| Pharmacyclics LLC, An Abbvie Company | $14.59 | 2023 | Imbruvica |
| Genentech USA, INC. | $14.41 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.97 | 2021 | |
| Springworks Therapeutics, INC. | $13.88 | 2024 | Ogsiveo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vera Maranci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.